Dako Omnis Dynamic Gap Staining
ثبت نشده
چکیده
منابع مشابه
Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies
The analysis of estrogen receptor (ER) and progesterone receptor (PR) expression levels by immunohistochemistry is an important part of the initial evaluation of breast cancer and critically important in treatment planning. Anti-ERα (clone EP1) and anti-PR (clone PgR 1294) antibodies are in development for the Dako Omnis automated staining platform. These antibodies are not yet commercially ava...
متن کاملChapter 1 Semantic Hypermedia Retrieval in Digital
Scientiic and economic success today mainly depend on getting information ahead of one's competitors. Although we live in an age of growing global information infrastructure, where access to huge amounts of data is not severely restricted, the selection of relevant data is the remaining challenge. Only data that is relevant in a given context is useful information. Developing highly selective t...
متن کاملOMNIS/Myriad on its Way to a Full Hypermedia Information System
The novel information retrieval system OMNIS is supported by the fulltext database system Myriad, and provides archiving, disclosing, and searching functions at drastically reduced costs. The user interface of OMNIS has been created in an intuitive way and compared with the Dexter Hypertext Reference Model, two main differences will be noticed: On the one hand, OMNIS does not support arbitrary ...
متن کاملOptimization of the Design of Omnis, the Observatory of Mutliflavor Neutrinos from Supernovae
A Monte Carlo code has been developed to simulate the operation of the planned detectors in OMNIS, a supernova neutrino observatory. OMNIS will detect neutrinos originating from a core collapse supernova by the detection of spalled neutrons from Pbor Fe-nuclei. This might be accomplished using Gd-loaded liquid scintillator. Results for the optimum configuration for such modules with respect to ...
متن کاملUse of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
BACKGROUND For non-small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Autostainer Link 48 (ASL48) platform. Optimised protocols are urgently needed for use of the 22C3 antibody concentrate to test PD-L1 express...
متن کامل